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Context: Besides short stature and gonadal dysgenesis, Turner syndrome (TS) is associated with
various abnormalities. Adults with TS have a reduced life expectancy, mainly related to structural
abnormalities of the heart and aorta, and an increased risk of atherosclerosis.
Objective: Our objective was to investigate the yield of an initial standardized multidisciplinary
screening in adult TS patients.
Design and Setting: This was an observational study at a multidisciplinary care unit for adult
women with TS.
Participants: Participants were adult women with TS (n 150). Mean age was 31.0 10.4 yr, with
47% karyotype 45,X.
Interventions:All womenwere consulted by an endocrinologist, a gynecologist, a cardiologist, an
otorhinolaryngologist, and when indicated, a psychologist. The screening included magnetic res-
onance imaging of the heart and aorta, echocardiography, electrocardiogram, dual-energy x-ray
absorptiometry, renal ultrasound, audiogram, and laboratory investigations according to inter-
national expert recommendations.
Main outcomemeasures:New diagnoses and prevalence of TS-associatedmorbidity were evaluated.
Results: Thirty percent of patients currently lacked medical follow-up, and 15% lacked estrogen
replacement therapy in the recent last years. The following disorders were newly diagnosed:
bicuspid aortic valve (n 13), coarctation of the aorta (n 9), elongation of the transverse aortic
arch (n  27), dilation of the aorta (n  34), osteoporosis (n  8), osteopenia (n  56), renal
abnormalities (n7), subclinicalhypothyroidism(n33), celiacdisease (n3),glucose intolerance
(n  12), dyslipidemia (n  52), hypertension (n  39), and hearing loss warranting a hearing aid
(n  8). Psychological consultation was needed in 23 cases.
Conclusions: Standardized multidisciplinary evaluation of adult women with TS as advocated by
expert opinion is effective and identifies significant morbidity. Girls with TS benefit from a careful
transition to ongoing adult medical care. (J Clin Endocrinol Metab 96: E1517–E1526, 2011)
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Turner syndrome (TS) is the result of complete or partialabsence of one X chromosome and one of the most
common sex chromosomal abnormalities with an inci-
dence of approximately one in 2000 in live-born girls (1).
Besides short stature, gonadal dysgenesis, anddysmorphic
features, TS is associated with a wide range of abnormal-
ities affecting nearly every organ system. Girls with TS are
usually treated with GH to increase adult height and with
estrogens to induce puberty. Hormone replacement ther-
apy (HRT) has to be started either after induction of pu-
berty or when estrogen production becomes insufficient
after initial spontaneous puberty.
Also in adulthood, TS is associated with significant
morbidity. There is an approximately 3-fold increased
age-related risk of mortality mainly caused by structural
cardiovascular anomalies and atherosclerosis related to
hypertension, diabetes, and dyslipidemia (2). In addition,
women with TS are prone to develop hypothyroidism,
osteoporosis, hearing loss, neurocognitive deficits, and
emotional problems (3, 4). In recent years, the enhanced
morbidity and mortality in adults with TS as well as the
ensuingneed for regularmedical attentionare increasingly
recognized. Especially the transition from pediatric to
adult care is a point of concern. Many young women are
lost to regular medical follow-up after discharge from the
pediatric clinic. Several specialized TS clinics have been
established in the United States and Europe to provide a
coordinated multidisciplinary care service. Based on the
experience of these centers, recommendations for stan-
dard of care and periodic screening have been put forward
(5–7). Despite these efforts, however, adult women with
TS often lack appropriate medical attention (8–12). In a
young French TS population, only 3.5% received appro-
priate medical care (8). In an adult U.S. TS population,
only one third had undergone the three examinations con-
sidered standard care for TSwomen, i.e. cardiac and renal
ultrasound and audiology (10). In a Belgian cohort,
12.7% lacked medical attention despite reported health
problems and 14.5% lacked HRT (9). An inventory
among Dutch TS women previously followed at a single
pediatric clinic showed that appropriate specialist care
was continued in only a minority (12).
Our multidisciplinary care unit for TS women was es-
tablished in 2005 and is the largest facility in The Neth-
erlands. Our approach was adapted from international
guidelines for care inTSpatients (5–7).Theyieldof screen-
ing as advocated in these guidelines was not previously
examined. In light of the question of whether the burden
of screening is justified by the yield of new diagnoses, and
whether the approach is cost-effective, the aim of this
study was to investigate the yield of an initial comprehen-
sive screening forTS-associatedmorbidity in a large group
of adult patients in a single Dutch center.
Patients and Methods
Patients
The study included 150 consecutive adult TS patients who
underwent an initial evaluation between May 2005 and June
2009. Mean age was 31.0  10.4 yr. The diagnosis of TS was
established by standard karyotyping of 30 peripheral lympho-
cytes (Table 1) (5).
Seventy-six percent of the women had received regular pedi-
atric care during childhood, and 56% of the women had been
treated with GH. Of 150 patients, 26 were directly referred for
transition frompediatric toadult carewithinour center. Seventy-
nine patients already received regular medical care by either a
gynecologist, cardiologist, and/or endocrinologist. Forty-five
patients had lacked medical follow-up by any specialist, with a
mean period of approximately 12 yr before attending the clinic.
The patients lacking medical follow-up were older than those
with medical follow-up (37.5 vs. 28.2 yr, P  0.01) and mean
time since diagnosis was longer (26.7 vs. 17.0, P  0.01).
TABLE 1. Patient characteristics (n  150)
Mean (SD) or %
Physical examination mean (SD)
Age (yr) 31.0 (10.4)
Height (cm) 153.2 (7.5)
Weight (kg) 61.6 (13.6)
BMI (kg/m2)a 26.2 (5.5)
Karyotype (%)
45,X 47
45,X/46,XXb 12
45,X/47,XXX 3
45,X/46,X,i(Xq) 14
45,X/46,X,del(X) 5
45,X/46,XY or marker Y 3
45,X/46,X,r(X) 3
46,X,i(Xq) 3
46,X,del(X) 2
Othersc 5
Pendingd 3
Medical care before investigation (%)
Direct transition from pediatric care 17
Specialist caree 53
Gynecologist 36
Internist 7
Cardiologist 2
Combination of more than one specialist 8
No medical care 30
a No difference in patients with and without diabetes.
b Including one patient with mosaicism trisomie 21 as well.
c Four patients with a mosaicism containing more than two cell lines,
two patients with a marker chromosome, and two patients with a
translocation with chromosome 13.
d Patients were diagnosed with TS elsewhere; confirmation in our
laboratory is pending.
e Of these patients 6 had lacked medical attention during a mean
period of 18.5 yr earlier in life.
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Screening
All patients underwent a standardized medical evaluation
adapted from expert opinion recommendations (5–7), which
consisted of consultation (history and physical) by an endocri-
nologist, gynecologist, cardiologist, otorhinolaryngologist, and,
in a selected group of patients, a psychologist. The work-up
included laboratory investigations and imaging, as indicated in
Table 2. Magnetic resonance imaging (MRI) scans were per-
formed using Avanto 1.5T (Siemens, Erlangen, Germany). The
protocol consists of dark blood (TSE db T1) and TRUFI images.
Diameters of the aorta were measured at the level of the sinuses
of Valsalva, the right pulmonary artery, the origin of the left
subclavian artery, the left atrium, the diaphragm, the kidney
arteries, and just above the bifurcation of the abdominal aorta.
Also, the largest cross-sectional diameters of the thoracic and
abdominal aorta were measured.
Echocardiographic evaluation was performed according to
the American Society of Echocardiography recommendations
(13). All examinations were performed by the same clinician
(J.T.), using the echocardiography machine Vivid 7 or System
Five (GE-Vingmed, Horten, Norway) connected to a phased-
array probe (2.5 and 3.5 MHz). Digitized measurements of the
aortic root were made in two-dimensional parasternal long-axis
views at end-diastole using the leading-edge technique at four
aortic levels: the annulus, the sinuses ofValsalva, the supraaortic
ridge, and the proximal ascending aorta. The largest aortic di-
ameter obtained in these views was described.
A 12-lead electrocardiogram (ECG) was performed to diag-
nose conduction or repolarization abnormalities.
Bone mineral density was measured at the lumbar spine (L1–
L4) and the right femoral neck using a QDR 4500 densitometer
(Hologic, Zaventem, Belgium). Bone mineral density was ex-
pressed as T- and Z-scores based on a normal reference
population.
Standard renal ultrasound was performed for assessment of
morphological abnormalities.
Hearing measurements were conducted according to stan-
dard audiometric methods (ISO 389) in a soundproof room. Air
conduction thresholds were measured in decibel hearing level at
0.25, 0.5, 1, 2, 4, and 8 kHz and bone conduction thresholds
were measured in decibel hearing level at 0.5, 1, 2, 4, and 8 kHz.
Data analysis and statistics
The analysis was restricted to the findings of the initial eval-
uation.Nodata of subsequent follow-up visits are presented.We
recorded all newly identified diagnoses. In case of previous di-
agnoses, relevant changes in treatmentwere recorded. Case find-
ing definitions are given in Table 3. For individual patients, TS-
related disease burden was calculated as the total number of
diagnoses among the following principal stigmata (maximum
score of 14): bicuspid aortic valve, coarctation of the aorta, elon-
gation of the transverse aortic arch, dilation of the aorta, dia-
betes, glucose intolerance, hypertension, dyslipidemia, osteopo-
rosis or osteopenia, (subclinical) hypothyroidism, celiac disease,
renal anomalies, liver enzyme disturbances, and hearing loss re-
quiring a hearing aid (14). Results are expressed as mean (SD),
unless mentioned otherwise. To analyze which patients benefit
most from the standardized screening, we performed a subgroup
analysis and compared the yield of diagnoses between patients
with different times since initial diagnosis, patients with or with-
out previous care, andpatientswithmonosomy45,X vs.patients
with other karyotypes. For subgroup analyses and comparisons
ofmeans, Student’s t test or2 testswereusedwhere appropriate.
We used Statistical Package for the Social Sciences version 16.0
(SPSS, Inc., Chicago, IL).
Data were collected under conditions of regular clinical care,
with institutional review board approval obtained for the use of
these data for scientific reasons.
Results
Newdiagnoses and total prevalence ofmorbidity are sum-
marized in Table 4 and Fig. 1. The disease burden in in-
dividual patientswas 1.21.2diagnoses before screening
and 3.5  1.9 diagnoses after screening (P  0.01). The
mean increase in disease burden was 2.3  1.5. When
comparing patients with 45,X with those with other
karyotypes, the former had a disease burden of 3.7 1.8
diagnoses after screening and the latter 3.3 2.0. Patients
with 45,X had significantly more new diagnoses during
TABLE 2. Screening protocol for adults with TS adapted from Bondy (5), Saenger et al. (6), Conway (7)
Investigation Once Every 1–2 yra Every 3–5 yra
Height, weight, blood pressure, auscultation of the heart X
Creatinine, blood urea nitrogen, ASAT, -GT, TSH, fT4, total cholesterol,
low-density cholesterol, high-density cholesterol, triglycerides, glucose,
HbA1c, urine dipstick analysis
X
Celiac serologyb X
Karyotype X
Renal ultrasound X
Pelvic ultrasound X
Audiogramc X
Cardiac ultrasound, including electrocardiogram X
MRI aorta (thoracic and abdominal) X
Bone mineral density measurement (DEXA) X
ASAT, Aspartate-aminotransferase; fT4, free T4; -GT, -glutamyl transpeptidase; HbA1c, glycated hemoglobin.
a Frequencies are increased when abnormalities are found.
b IgA antibodies to tissue transglutaminase and endomysium; in case of IgA deficiency, IgG antibodies were measured.
c Repeat at age of 40.
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screeningwhen comparedwith patients with other karyo-
types (2.6  1.5 vs. 2.0  1.5). Age correlated positively
with the disease burden before screening (r  0.485) and
after screening (r  0.689) and the number of new diag-
noses during screening (r  0.403).
Anomalies of the heart and aorta
Before the current investigations, 81 patients (54%)
had undergone cardiac ultrasound and 16 (10.7%) MRI.
Eighteen had a previous diagnosis of structural cardiac
and/or aortic anomalies. Five had undergone surgery. Re-
evaluation yielded additional aortic anomalies in six.
Screening of 132 patients without previously known car-
diac or aortic anomalies consisted of MRI and cardiac
ultrasound (n 100),MRI only (n 12), and ultrasound
only (n 9).MRI results are pending in nine. In addition,
MRI was not performed in six because of claustrophobia
and in five because of recent cardiovascular screening in-
cluding MRI. This yielded one or more congenital anom-
alies in 40 patients (30.3%). Fifteen of these patients had
an additional dilation of the aorta. In 15 other patients,
aortic dilation was an isolated finding. In the group with
newdiscovered cardiac and aortic abnormalities (n 55),
25 had previously undergone cardiac screening by cardiac
ultrasound and MRI in one. In five patients, a bicuspid
aortic valve was missed by previous screening. All other
new diagnoses were attributable to screening with an ad-
ditional MRI: elongation, mild coarctation, and dilation
of the aorta. See Fig. 2 for images.
Inwomenwith karyotype 45,X, significantlymore struc-
tural cardiovascular abnormalities were diagnosed com-
pared with women with other karyotypes (Supplemental
Table 1, published onThe Endocrine Society’s JournalsOn-
line web site at http://jcem.endojournals.org). Furthermore,
the time since the initial diagnosis of TS correlated positively
with a higher number of newly diagnosed structural cardio-
vascular abnormalities. (Supplemental Table 2).
An ECG was performed in 134 patients. All patients
showed a sinus rhythm, including eight patientswith sinus
tachycardia (100 beats per minute) and one with sinus
bradycardia (60 beats per minute). In 53.4% of the pa-
tients, the ECG was normal, 37.3% showed repolariza-
tion abnormalities (STT abnormalities), 17.2%QTc pro-
longation, 4.5% other conduction abnormalities, 3.0%
left axis deviation, and 0.7% right axis deviation.
Concerning the diastolic and systolic function, we
found that 2.0% of the women (n  3) had an impaired
cardiac function; one patient had an ejection fraction of
43.8%, and two patients had a dilated right ventricle, one
due to an atrium septum defect and one due to a partial
anomalous pulmonary venous return. We found one pa-
tient with left ventricular hypertrophy secondary to a bi-
cuspid aortic valve with stenosis (15).
Atherosclerosis and risk factors
Two patients had a history of myocardial infarction at
31 and 44 yr of age. Seventeen patients (11.3%) were
current smokers. Mean body mass index (BMI) was
26.2 5.5 kg/m2 (52.7% had a BMI25 kg/m2; 20.7%
had a BMI 30 kg/m2).
Seven patientswere previously diagnosedwith diabetes
(four insulin dependent) and two with impaired glucose
intolerance. No new cases of diabetes were encountered.
TABLE 3. Case finding definitions
Case finding definition
Congenital anomalies of
the heart/aorta
Bicuspid aortic valve, coarctation of
the aorta, elongation of the
transverse aortic arch
Dilation of the aorta Dilation of the ascending aorta
based on BSA corrected
values (17, 40) and/or local or
fusiform dilation of the
descending aorta
Diabetes Diabetes: random glucose 11.1
mmol/liter or Hba1c 6.5 mmol/
liter
Impaired glucose tolerance:
random glucose between 7.8
and 11.1 mmol/liter or HbA1c
between 5.7 and 6.4% (41)
Hypertension Use of antihypertensive medication
or systolic blood pressure 140
mm Hg and/or a diastolic blood
pressure 90 mm Hg
Dyslipidemia TC 5.50 mmol/liter and/or HDL-
C 1.10 mmol/liter and/or LDL-
C 3.50 mmol/liter and/or
TG 2.20 mmol/liter (random
lipid profiles)
Diminished bone mineral
density
Osteoporosis: T-score 2.5 SD;
osteopenia: T-score between
the 1.0 and 2.5 SD
Hypothyroidism Hypothyroidism: TSH above upper
reference limit of 4.0 mEq/liter
and fT4 below lower reference
limit of 8.0 pmol/liter
Subclinical hypothyroidism: TSH
4.0 mEq/liter and fT4 within
normal range (8.0–22.0 pmol/
liter)
Structural anomalies of
the kidney
Horseshoe kidney, duplication of
the collecting system, agenesis,
and rotation as TS-specific renal
malformations
Liver enzyme elevation g-GT 35 U/liter and/or ASAT
40 U/liter
ASAT, Aspartate-aminotransferase; fT4, free T4; -GT, -glutamyl
transpeptidase; HbA1c, glycated hemoglobin; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein; TC, total
cholesterol; TG, triglycerides.
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Seventeen patients were known with hypertension, 10
of whom had insufficient blood pressure control. An ad-
ditional 39 patients had an elevated blood pressure based
on supine office sphygmanometric measurements at time
of consultation. In the context of individual cardiovascu-
lar risk, medication was started in seven.
Eight patients were previously diagnosed with dyslip-
idemia, and three of them were currently taking a statin.
In the others, lipid profile was abnormal in 36.6%.
Fertility and HRT
In 36 patients, spontaneousmenarche had occurred. In
the remaining 114 patients, puberty was induced by es-
trogen therapy in 107. In three patientswith 45,X, fertility
treatment with egg donation resulted in one successful
pregnancy. Spontaneous pregnancies occurred in two pa-
tientswithmosaicism.Twoother patientswithmosaicism
attempted to become pregnant with fertility treatment,
one including egg donation, but did not succeed. Five pa-
tients were known with a (partial) Y chromosome. Pro-
phylactic gonadectomy took place except in two; one re-
fused, and in the other, the SRY gene was absent.
Gynecological ultrasound in 117 patients revealed a
uterus subseptus in two, a uterine myoma in two, and a
polyp in one.
At referral, 146 women were below 52 yr of age, the
median age for menopause. In this group, 23 women
lacked any form of HRT, including seven with a sponta-
neous menstrual cycle and one because of current fertility
treatment.
The different regimes of the 124 (one above 52 yr of
age) patients already on HRT were continuous combined
(15.3%), sequential combined (54.0%), oral contracep-
tives (28.2%), and estrogen only (2.4%). Eight of them
previously lacked HRT for a mean duration of 6 yr. In 31
TABLE 4. TS-associated morbidity (n  150)
Previous
diagnoses (n)
Changes in
treatment (n)
New
diagnoses (n)
Observed
frequency (%)
Frequency literature (%)
(3–5, 11, 17, 23, 24, 26,
27, 34, 38, 42, 43)
Bicuspid aortic valve 12 0 10 19a 14–34
Aortic coarctation 2 0 6 9a 7–14
Bicuspid valve and coarctation 3 0 4b
Elongation of the transverse
aortic arch
0 0 27 18a 50
Dilation of the aorta 4c 0 34 25a 3–42
Diabetes type 1 2 0 0 1 0.5–5
Diabetes type 2 5 0 0 3 3–25
Glucose intolerance 2 0 12 9 7–50
Hypertension 17 5 39d 37 24–50
Dyslipidemia 8 0 52 40 37–50
Osteoporosis 10 8 12e
Osteopenia 22 56 52e
Osteoporosis or osteopenia 32 4 64 64e 50–80
Hypothyroidism 17 11 0 11 16–30
Subclinical hypothyroidism 7 2 33f 27
Celiac disease 0 0 3 2 4–6
Renal anomalies 23g 0 7h 20i 28–38
Liver enzyme disturbances 5 0 45j 33 36–80
Hearing loss requiring aid 31 1 8k 26l 27–44
a Possible underestimation because of cardiac ultrasound in all, in 20 no MRI.
b Including one recoarctation of the aorta.
c Three in patients with a bicuspid aortic valve and/or coarctation.
d Seven warranting medication.
e Possible underestimation because of bone mineral density measurement in 146 patients.
f Five warranting medication.
g Horseshoe kidney (n  15), duplication of the collecting system (n  5), unilateral renal agenesis (n  2), and malrotation (n  1).
h Horseshoe kidney (n  3), duplication of the collecting system (n  4).
i Possible underestimation because of renal ultrasound in 142.
j Forty-six patients had a mild elevation of -glutamyl transpeptidase and/or aspartate-aminotransferase (ASAT). ASAT was below twice the upper
limit in all cases.
k Additional 35 with hearing impairment.
l Possible underestimation because of ear, nose, and throat consult in 110 patients.
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patients, the regimenwas intensifiedorotherwise adjusted
because of decreased bone mineral density (n  5), me-
trorrhagia, dysmenorrhea, and/or the patient’s preference
to switch to a noncyclic regimen (n  26).
Bone mineral density
Forty-six patients (30.7%) had a history of trauma-asso-
ciated fractures.Forty-threepatients (28.7%)hadpreviously
undergone a bone mineral densitometry, yielding osteopo-
rosis in 10 and osteopenia in 22. Ten of these patients were
taking bisphosphonates. Based on 26 repeated bonemineral
density measurements, four patients needed adjustment of
therapy. In 118 patients without a previous diagnosis, 111
bone mineral density measurements were performed. In pa-
tients with osteoporosis (n 8) or osteopenia (n 56), life-
style interventions enhancing bone health were advocated,
i.e. adequate calcium intake, exposure to sunlight, and
weight-bearing exercise. Additionally, HRT was started or
intensified in eight, calcium/vitaminD supplementationwas
started ineight,bisphosphonateswereprescribed intwo,and
a combination of calcium/vitamin D supplementation and
change in HRT occurred in two.
Thyroid disease
Seventeenpatients hadahistoryof hypothyroidismand
were taking thyroid hormone. The dose needed adjust-
ment in 11 patients. We found 33 cases of new subclinical
hypothyroidism, prompting supplementation of thyroid
hormone in five symptomatic cases.
Kidney malformations
Seventy-two patients (48%) had previously undergone
renal ultrasound showing anomalies in 23 patients. Three
patients had undergone surgical interventions.
Of the remaining 78 patients, 70 underwent a renal
ultrasound yielding anomalies in seven. Renal function
was normal in all patients. Isolated erythrocy-
turia was found in two patients without struc-
tural anomalies or proteinuria. In eight pa-
tients, renal ultrasound results are pending.
Hearing loss
Thirty-one patients already had a hearing
aid, including four patients with a bone-an-
chored hearing aid. Of 119 without a previous
diagnosis, 78 underwent audiology indicating
significant hearing impairment in 43 patients,
with the requirement of a hearing aid in eight.
Psychological problems
Twenty-three patients (meanage38yr) con-
sulted the psychologist with the following rea-
sons: need for support in accepting TS-related
limitations in daily life (70%), low self-esteem (55%),
nonassertiveness (45%), lackof social support (25%), and
infertility-related emotional problems (10%).
Abnormalities regarding celiac disease and liver en-
zyme disturbances are specified in Table 4.
When comparing thewomenwithout previousmedical
care and the women with adult specialist care to the
womenwithdirect transition frompediatric carewe found
that a larger number of new diagnoses were found in the
first group (Table 5).
Discussion
Weinvestigated theyieldof comprehensive screening forTS-
associatedmorbidity in a large group of adult TS patients in
asingleDutchcenter.Multidisciplinaryevaluation identified
many patients with previously unknown diagnoses, includ-
ingcardio-aortic anomalies (40.7%),hypertension (26.0%),
dyslipidemia (34.7%), impaired glucose tolerance (8.0%),
current or previous lack of HRT despite estrogen deficiency
(15.3%), osteoporosis (5.3%), osteopenia (37.3%), subclin-
ical hypothyroidism (22.0%), and hearing loss requiring a
hearing aid (5.3%). In individual patients, on average, two
new major TS-related diagnoses were found. Patients with-
out previous specialist care benefited most from the
screening.
In the majority of patients, 76% in our cohort, TS was
diagnosed in childhood triggered by dysmorphic features,
impaired growth, and/or delayed puberty. Ensuing GH
treatment and induction of puberty requires strict pediat-
ric follow-up. Many patients are lost to follow-up after
discharge from pediatric care (8–11). In the present co-
hort, one third lacked any form of ongoing specialist care.
Lack of care was most prevalent among older patients. It
is unclear which patients are prone to lack ongoing med-
FIG. 1. Frequencies of TS-associated morbidities in 150 TS patients.
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ical care. It might be that socioeconomic factors play a
role. We have insufficient data to investigate this. How-
ever, inTheNetherlands, health insurance is obligatory by
law and entitles all patients to identical care.
The importance of awell-organized transition frompe-
diatric to adult care was stressed by the Turner Syndrome
Consensus Study Group (5). Besides a well-organized
transition, a multidisciplinary periodic screening of adult
womenwithTS is advocated in international expert-based
guidelines, mainly because many disorders do not present
until adult age (5–7). Our current finding of a
significant previously unrecognized morbidity
demonstrates the effectiveness of such an
approach.
Medical care in adult women with TS is
mainly aimed at reduction of the approxi-
mately 3-fold increase in age-related risk of
cardiovascular mortality (2). The necessary
screening for structural cardiac and aortic
anomalies had been omitted in half of our pa-
tients. Current screening revealed unknown
cardiac and/or aortic anomalies in approxi-
mately 40% of the patients. Cardio-aortic
anomalies and hypertension are assumed to in-
crease the risk of aorta dilation and dissection
(4, 16, 17). The prevalence of aortic dilation
increases with age, but dilation in TS can al-
ready be present in the second decade of life
(18, 19). Aortic dissection occurs at relatively
young age (third decade) with an age-depen-
dent incidence of 15–50 cases in 100,000 TS
years compared with six cases in the normal
population (20). Considering the fact that aor-
tic abnormalities are usually asymptomatic un-
til complications occur, periodic screening of
the aortic diameter appears to be justified.Car-
diac follow-up can be performed using ultra-
sound and MRI, the latter having the advan-
tage of superior imaging of the coarctation site
and the distal aorta (16, 19). In a recent report,
Matura et al. (17) advise to use aorta size index
(aortic diameter/body surface area) instead of
absolute aortic diameter because of limited
availability of reference values for aortic diameters. The
authors suggest strict follow-up in case of an aorta size
indexof at least 2.0 cm/m2andevaluation forprophylactic
intervention in case of an aorta size index of at least 2.5
cm/m2 in combination with an absolute aorta diameter
above 3.5 cm. In (induced) pregnancy, the risk of dissec-
tion is even higher, and in one retrospective study, the
pregnancy-related mortality is estimated at 2% (21). Car-
diovascular screening is strongly advised before and dur-
FIG. 2. MRI and MRA images of anomalies of the heart and aorta. A, Coarctation of
the aorta; B, dilation of the aorta; C, bicuspid aortic valve; D, elongation of the
transverse aortic arch. [Reproduced with permission from K. Freriks et al.: Ned
Tijdschr Geneeskd 151:1616–1622, 2007 (44) © Nederlands Tijdschrift voor
Geneeskunde.]
TABLE 5. Impact of previous care on percentage of new diagnoses
Direct transition
from pediatric care
(mean age 19.0  1.5 yr)
Preceding adult
specialist care (mean age
31.3  9.1 yr)
No specialist
care (mean age
37.5  9.2 yr)
Structural cardiovascular abnormalities (%) 34.6 31.7 60.0a
Osteoporosis or osteopenia (%) 53.9 32.9a 53.3
Cardiovascular risk factors (%) 34.6 51.9 57.8a
(Subclinical) hypothyroidism (%) 15.4 15.2 37.8a
a Significant compared with women directly referred from pediatric care.
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ing each pregnancy. In fact, pregnancy is discouraged in
patients with congenital cardiac and aortic anomalies, hy-
pertension and,/or an aortic size index (aortic diameter/
body surface area) of at least 2.0 cm/m2 (22).
Besides structural anomalies, TS in adults is associated
with an unfavorable risk profile for cardiovascular dis-
ease. The prevalence of atherosclerosis is doubled (23). In
the present young population, 37% had hypertension,
40% had an abnormal nonfasting lipid profile, 5% had
diabetes, and half of the patients were overweight. Prev-
alence of diabetes type 2 in the TS population is increased
compared with the general population. Focusing on the
age group around 30, incidence numbers vary. Bakalov et
al. (24) found a prevalence of diabetes type 2 in 25% of a
young TS population (age 35.4 11.3 yr, BMI 28.9 7.7
kg/m2), whereas Landin-Wilhelmsen et al. (25) reported a
prevalence of 3% in a similar age group (age 33.7 11 yr,
mean BMI 25.9  5.0 kg/m2). Probably this difference is
related to differences in BMI.Nevertheless, the clearly un-
favorable cardiovascular risk profile at young age suggests
that patients benefit from screening and careful manage-
ment. Intervention trials, however, are lacking.
The pathophysiology of the increased prevalence of au-
toimmune disease, especially in association with Xi(Xq)
genotypes, remains unknown. We confirm a high preva-
lence (38%) of hypothyroidism, including subclinical
cases. Previous studies have indicated that 16–30%of the
TS patients have elevated TSH levels and that 27–45% of
the TS patients have positive thyroid antibody titers (26,
27). Furthermore, we found three patients with proven
celiac disease. It has been shown that celiac disease ismore
common in the TS population with a prevalence of 4–6%
(28).Ongoingperiodic screening forbothhypothyroidism
and celiac disease seems reasonable because incidences
increase with age. Vigilance for additional less common
TS-related autoimmune diseases is essential (28–30).
Another important issue that needs ongoing medical
attention, at least until normal age ofmenopause, is HRT.
HRT in estrogen-deficient women has a positive effect on
bone mineral density, prevents vaginal atrophy, and was
shown to have a favorable impact on cardiovascular risk
in TS (31). In our cohort, 15% lacked HRT, which is
similar to observations in other countries (9, 32). In about
half of the cases, HRT was discontinued by the patient
because of self-reported side effects or unawareness of the
reasons for HRT. In others, HRT was never started. One
reason could be that physiciansmight be unjustly reserved
regarding HRT because of the relationship with breast
cancer in elderly postmenopausal women (33).
Two thirds of our TS patients were found to have a low
bonemineral density correlatedwith older age and lack of
HRT. TS is associated with an intrinsic structural bone
defect, which is worsened by estrogen deficiency (34).
Because short stature can cause false low areal bone
mineral density, it is possible that the high frequency of
osteoporosis observed in TS patients based on bone
mineral density measurements is in fact an overestima-
tion (35). Nevertheless, a higher fracture risk in TS,
varying from 24–32%, has been established, warrant-
ing careful observation and treatment of bone health,
including optimal HRT (32, 36).
During childhood, the vast majority of TS patients suf-
fer from recurrent glue ear, otitis media, and resulting
conductive hearing loss, probably related to an abnormal
Eustachian tube (37). During adulthood, conductive and
perceptive hearing loss frequently occurs, the latter often
with either a mid- or high-frequency dip. In our group,
more than 25%of patients suffered from significant hear-
ing impairmentwarranting the use of a hearing aid, which
is similar to previous reports. Hultcrantz (38) found that
27% of TS patients needed a hearing aid (n  324; age
range 4–68) and as many as 44%when focusing on those
aged above 35 yr.
Besides physical health issues, women with TS often
deal with (neuro)psychological problems (39). Our study
confirms that many TS women experience difficulties in
regard to acceptance of limitations related to TS and low
self-esteem. Remarkably, emotional problems related to
infertility were mentioned by only a small minority.
In conclusion, standardized multidisciplinary evalu-
ation of adult women with TS yields significant previ-
ously undiagnosed morbidity. TS patients are therefore
likely to benefit from a careful transition from pediatric
into adult medical care, consisting of a multidisci-
plinary service with standardized screening for TS-as-
sociated morbidity. To what level our approach improves
long-termmorbidity,mortality,andhealth-relatedqualityof
life remains to be investigated. The actual benefit should
also be weighed against the costs of screening and the
risk of medicalization.
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